Arch Oncology to Collaborate with Merck on Phase 1/2 Clinical Trial of Anti-CD47 Antibody AO-176 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Select Solid Tumors
With Encouraging Safety and Anti-tumor Activity for AO-176 Monotherapy in Phase 1 Trial, Advancing AO-176 in Combination with Anti-PD-1BRISBANE, Calif....